ERBB2 and TOP2A in breast cancer: A comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2391-2401

  Brase, Jan C ^a   Schmidt, Marcus ^b   Fischbach, Thomas ^b   Sültmann, Holger ^a   Bojar, Hans ^e   Koelbl, Heinz ^b   Hellwig, Birte ^c   Rahnenführer, Jörg ^c   Hengstler, Jan G ^c   Gehrmann, Mathias C ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

^d Siemens Medical Solutions Diagnostics   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; RNA; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; PILOT PROJECTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RNA, NEOPLASM; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951019861     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2471     Document Type: Article

References (49)

1. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-1998 (Pubitemid 32045895)
2. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-1360
3. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-1116 (Pubitemid 34517647)
4. Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIα - simultaneous drug targets in cancer. Comb Chem High Throughput Screen 2003;6:455-470
5. Hengstler JG, Lange J, Kett A, et al. Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-3214 (Pubitemid 29316024)
6. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol 2002;3:235-243
7. Knoop AS, Knudsen H, Balslev E, et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-7490 (Pubitemid 46291811)
8. Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-734 (Pubitemid 351878451)
9. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II α and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009;101:644-650
10. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II α gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-150 (Pubitemid 29416439)
11. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001;12:1081-1089 (Pubitemid 32834488)
12. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847 (Pubitemid 30626942)
13. Slamon DJ, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. SABC 2007.
14. Schmidt M, Bremer E, Hasenclever D, et al. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer 2007;96:241-247 (Pubitemid 46160628)
15. Schmidt M, Hasenclever D, Schaeffer M, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 2008;14:5849-5855
16. Brulport M, Schormann W, Bauer A, et al. Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers. Hepatology 2007;46:861-870 (Pubitemid 47436132)
17. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-194 (Pubitemid 36109732)
18. Schiffer IB, Gebhard S, Heimerdinger CK, et al. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res 2003;63:7221-7231 (Pubitemid 37413461)
19. Schmidt M, Bohm D, von Torne C, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-5413
20. Schmidt M, Victor A, Bratzel D, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009;20:258-264
21. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679 (Pubitemid 40260888)
22. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-3214 (Pubitemid 46944903)
23. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-1246 (Pubitemid 46640570)
24. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Predictors of primary breast cancers responsiveness to preoperative epirubicin/ cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 2005;3:32. (Pubitemid 41522380)
25. Rody A, Karn T, Ruckhaberle E, et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009;113:457-466
26. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-2581
27. Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13: IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008;14:2601-2608
28. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826 (Pubitemid 40051905)
29. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317-4323 (Pubitemid 46630790)
30. Mohrmann G, Hengstler JG, Hofmann TG, et al. SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer. Int J Cancer 2005;116:547-554 (Pubitemid 41099190)
31. Steiner E, Plata K, Interthal C, et al. Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol 2007;28:95-97 (Pubitemid 46697776)
32. Hengstler JG, Bockamp EO, Hermes M, et al. Oncogene-blocking therapies: new insights from conditional mouse tumor models. Curr Cancer Drug Targets 2006;6:603-612 (Pubitemid 44691002)
33. Schmidt M, Hengstler JG, von Torne C, Koelbl H, Gehrmann MC. Coordinates in the universe of node-negative breast cancer revisited. Cancer Res 2009;69:2695-2698
34. Steiner E, Pollow K, Hasenclever D, et al. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol Oncol 2008;108:569-576
35. Spangenberg C, Lausch EU, Trost TM, et al. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res 2006;66:3715-3725
36. Trost TM, Lausch EU, Fees SA, et al. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res 2005;65:840-849
37. Gancberg D, Jarvinen T, di Leo A, et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 2002;74:113-120 (Pubitemid 34816216)
38. Schmidt M, Lewark B, Kohlschmidt N, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005;7:R256-66.
39. Arriola E, Marchio C, Tan DS, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008;88:491-503. (Pubitemid 351581454)
40. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II α amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007;106:181-189 (Pubitemid 350045015)
41. Jarvinen TA, Liu ET. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIα (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006;6:579-602.
42. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24:2428-2436 (Pubitemid 46630618)
43. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-744 (Pubitemid 351264386)
44. Hermes M, Schormann W, Brulport M, et al. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer 2008;98:1525-1532 (Pubitemid 351652324)
45. Hausherr CK, Schiffer IB, Gebhard S, et al. Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model. Mol Carcinog 2006;45:302-308 (Pubitemid 43749197)
46. Tubbs R, Barlow WE, Budd GT, et al. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 2009;27:3881-3886
47. Durbecq V, Desmed C, Paesmans M, et al. Correlation between topoisomerase-IIα gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 2004;25:1473-1479
48. Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005;123:889-895 (Pubitemid 40740688)
49. Cardoso F, Durbecq V, Larsimont D, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004;24:201-209